ImmuCell Corp. (ICCC)
9.79
-0.05
(-0.51%)
USD |
NASDAQ |
Sep 09, 10:56
ImmuCell Net Income (Quarterly) : 1.835M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.835M |
| March 31, 2026 | 1.942M |
| December 31, 2025 | -2.849M |
| September 30, 2025 | -0.1397M |
| June 30, 2025 | 0.5019M |
| March 31, 2025 | 1.447M |
| December 31, 2024 | 0.515M |
| September 30, 2024 | -0.7017M |
| June 30, 2024 | -1.532M |
| March 31, 2024 | -0.4379M |
| December 31, 2023 | -1.14M |
| September 30, 2023 | -0.94M |
| June 30, 2023 | -1.380M |
| March 31, 2023 | -2.315M |
| December 31, 2022 | -1.668M |
| September 30, 2022 | -0.6551M |
| June 30, 2022 | -0.6841M |
| March 31, 2022 | 0.5133M |
| December 31, 2021 | 0.0741M |
| September 30, 2021 | 0.1478M |
| June 30, 2021 | 0.1411M |
| March 31, 2021 | -0.4413M |
| December 31, 2020 | 0.189M |
| September 30, 2020 | -0.3229M |
| June 30, 2020 | -0.7658M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1223M |
| December 31, 2019 | -0.31M |
| September 30, 2019 | -0.5025M |
| June 30, 2019 | -0.6272M |
| March 31, 2019 | 0.1446M |
| December 31, 2018 | -1.052M |
| September 30, 2018 | -0.25M |
| June 30, 2018 | -0.7984M |
| March 31, 2018 | -0.2211M |
| December 31, 2017 | -0.195M |
| September 30, 2017 | -0.3393M |
| June 30, 2017 | -0.2184M |
| March 31, 2017 | 0.5842M |
| December 31, 2016 | 0.03M |
| September 30, 2016 | 0.0349M |
| June 30, 2016 | -0.0092M |
| March 31, 2016 | 0.4524M |
| December 31, 2015 | 0.289M |
| September 30, 2015 | 0.3513M |
| June 30, 2015 | 0.0941M |
| March 31, 2015 | 0.4791M |
| December 31, 2014 | 0.131M |
| September 30, 2014 | 0.0103M |
| June 30, 2014 | -0.2948M |
| March 31, 2014 | -0.0133M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.186M |
| Total Expenses (Quarterly) | 5.352M |
| EPS Diluted (Quarterly) | 0.1996 |
| Enterprise Value | 92.96M |
| Gross Profit Margin (Quarterly) | 33.92% |
| Profit Margin (Quarterly) | 25.53% |
| Earnings Yield | 0.86% |
| Operating Earnings Yield | 2.10% |
| Normalized Earnings Yield | 1.409 |